Timing note: HCA’s Q2 call is scheduled for today, Friday, July 24, 2026, at 9:00 a.m. Central / 10:00 a.m. Eastern—not tomorrow. The company already preannounced preliminary results and revised guidance on July 14, so the call’s commentary will matter considerably more than the headline numbers. (investor.hcahealthcare.com)
HCA’s preliminary Q2 results were superficially strong: revenue and EPS exceeded prior Wall Street expectations, admissions accelerated, and emergency-room traffic remained healthy. But the quality of earnings deteriorated.
The expiration of enhanced exchange subsidies and related administrative changes are producing more uninsured patients than HCA initially modeled. At the same time, surgical volumes—generally higher-value activity—declined. A large, largely retrospective Florida Medicaid supplemental-payment benefit helped offset these pressures, but adjusted EBITDA margin still contracted.
Consequently, investors already know most of the quarter’s numbers. The important questions are now:
| Q2 metric | Preliminary Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $20.230B | $18.605B | +8.7% |
| Net income attributable to HCA | $1.699B | $1.653B | +2.8% |
| Diluted EPS | $7.62 | $6.83 | +11.6% |
| Adjusted EBITDA | $4.027B | $3.849B | +4.6% |
| Adjusted EBITDA margin | 19.9% | 20.7% | -80 bps |
| Same-facility admissions | — | — | +2.5% |
| Equivalent admissions | — | — | +2.7% |
| ER visits | — | — | +3.6% |
| Inpatient surgeries | — | — | -2.3% |
| Outpatient surgeries | — | — | -3.4% |
The preliminary revenue of $20.23 billion was above the roughly $19.43 billion analyst average cited by Reuters, while preliminary EPS of $7.62 was also ahead of expectations. Nevertheless, the guidance reduction and worsening payer mix overshadowed the headline beat. (investor.hcahealthcare.com)
EPS increased almost 12%, but net income grew less than 3%. Diluted shares declined approximately 7.9% year over year, to 222.8 million, meaning repurchases supplied most of the gap between net-income and EPS growth.
That is not inherently negative—HCA has historically generated substantial cash and returned capital aggressively—but investors should distinguish per-share accretion from underlying operating growth.
HCA estimates that the shift toward uninsured patients reduced Q2 pretax income by approximately $400 million. That figure includes a $75 million upward revision to the company’s previous estimate of the Q1 impact.
HCA consequently raised its estimated full-year exchange-related headwind:
| 2026 exchange impact | Previous estimate | Revised estimate |
|---|---|---|
| Unfavorable pretax impact | $(600)M–$(900)M | $(1.0)B–$(1.2)B |
The midpoint deterioration is approximately $350 million.
At Q1 earnings, management estimated a $150 million exchange impact and said exchange equivalent admissions had declined approximately 15%, while uninsured equivalent admissions increased roughly 16%. Management then believed the initial $600 million–$900 million annual estimate remained adequate. The Q2 revision shows that the issue developed materially faster than expected. (investor.hcahealthcare.com)
Management should clarify:
Based on the disclosed Q1 and Q2 estimates, HCA has absorbed approximately $550 million of exchange-related pressure during the first half. The revised guidance midpoint implies approximately another $550 million in the second half. That assumption may prove reasonable, but management needs to explain why Q2’s deterioration should not continue accelerating.
HCA recognized approximately $400 million of incremental net benefit from Medicaid supplemental-payment programs in Q2, primarily associated with Florida’s approved state-directed payment program covering the period from October 1, 2024 through June 30, 2026.
The company also revised its full-year Medicaid supplemental-payment assumption:
| 2026 Medicaid supplemental-payment change | Previous estimate | Revised estimate |
|---|---|---|
| Incremental net benefit | $(50)M–$(250)M | +$300M–+$500M |
This favorable revision more than offsets the higher exchange headwind on a simple midpoint basis. Yet HCA still reduced EBITDA and EPS guidance. That highlights the importance of weaker surgical mix, margin pressure and potentially other operating assumptions. (investor.hcahealthcare.com)
Investors should not treat the entire Q2 Medicaid benefit as recurring quarterly earnings. Much of it covers prior periods, and future payments depend on program approvals, structure and timing.
The call needs to separate:
Admissions and ER visits accelerated substantially from Q1:
| Same-facility volume growth | Q1 2026 | Preliminary Q2 2026 |
|---|---|---|
| Admissions | +0.9% | +2.5% |
| Equivalent admissions | +1.3% | +2.7% |
| ER visits | +0.3% | +3.6% |
| Inpatient surgeries | -0.3% | -2.3% |
| Outpatient surgeries | -1.7% | -3.4% |
Q1 had been affected by weak respiratory activity and winter weather, so a rebound was expected. The concern is that the rebound did not extend to surgery. HCA said Q2 included an unfavorable service-mix shift primarily related to lower surgical volume. (investor.hcahealthcare.com)
The distinction matters. Emergency visits and admissions can generate strong demand statistics, but elective and complex surgical procedures often produce more attractive economics. If exchange coverage losses are causing patients to defer planned procedures, the payer-mix and service-mix problems may be linked rather than independent.
Key questions include:
Adjusted EBITDA increased 4.6%, but revenue grew 8.7%, producing an 80-basis-point margin contraction to 19.9%. This follows a 50-basis-point decline in Q1, when adjusted EBITDA margin was also 19.9%.
Management previously outlined approximately $400 million of 2026 resiliency benefits, including labor productivity, revenue-cycle initiatives, case-management improvements and AI-supported workflows. Q1 labor and supply ratios improved, but those gains were outweighed by other operating expenses and adverse operating leverage.
For Q2, investors should focus on:
| 2026 metric | Previous range | Revised range | Midpoint change |
|---|---|---|---|
| Revenue | $76.5B–$80.0B | $77.0B–$79.5B | Unchanged at $78.25B |
| Net income | $6.495B–$7.035B | $6.3B–$6.7B | Down approximately $265M |
| Adjusted EBITDA | $15.55B–$16.45B | $15.4B–$16.1B | Down $250M |
| Diluted EPS | $29.10–$31.50 | $28.70–$30.50 | Down $0.70 |
| Capital expenditures | $5.0B–$5.5B | Unchanged | — |
The revenue midpoint was maintained, while profit expectations declined. That is a classic indication of lower revenue quality and weaker conversion to earnings.
Through the preliminary first half, HCA has generated:
At the revised guidance midpoint, HCA therefore needs roughly $38.91 billion of second-half revenue and $7.92 billion of second-half adjusted EBITDA. The arithmetic is achievable, but the quality of the first half—particularly the retrospective Florida payment—means management’s underlying bridge is more important than the totals.
HCA repurchased $1.57 billion of stock in Q1 at an average price of approximately $497.63, with $9.18 billion remaining under its authorization at March 31. The share price subsequently fell sharply following the Q2 preannouncement.
Investors should listen for:
Aggressive repurchases could support EPS, but they do not resolve the payer-mix and margin questions that will determine the stock’s valuation.
The headline quarter has already been released, and it is unlikely that small final adjustments to revenue or EPS will drive the investment reaction. The call will instead be a test of management’s credibility around the revised outlook.
The most important disclosure would be a clean earnings bridge separating:
A constructive call would establish that Q2 represented the peak exchange disruption, that surgery is recovering, and that the revised guidance contains adequate conservatism. Without that evidence, investors are likely to view the preliminary EPS beat as buyback-assisted and the Medicaid benefit as temporary—leaving the focus squarely on margin compression and the risk to 2027 earnings.